AACR COVID-19 and Cancer Virtual Meeting: Cancer Researchers Shift Focus to the Pandemic
In the global battle against the COVID-19 pandemic, cancer researchers are proving to be formidable forces. Armed with deep...
In the global battle against the COVID-19 pandemic, cancer researchers are proving to be formidable forces. Armed with deep...
Guest Post by Barbara A. Conley, MD National Cancer Institute (NCI)
Cancer health disparities are driven by the compounding of multiple factors, including gaps in research resulting from insufficient representation...
“Are you ready to have a great meeting?” Robert Vonderheide, MD, DPhil, asked the nearly 11,000 attendees gathered in...
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
Four of the 2023 GSITA recipients explain how the program has benefited their careers.
A new fellowship program is giving 20 early-career researchers a window into oncology drug development and the regulatory review...
As infections from SARS-CoV-2 began to rapidly spread across the United States in early 2020, many nonessential medical procedures, including cancer screenings, were...
As a scientific organization focused on preventing and curing all cancers, the American Association for Cancer Research (AACR) embraces...
The spectacular sight of the AACR Annual Meeting 2019 Opening Ceremony, held Sunday, March 31, at the Georgia World...
Twenty years ago, the American Association for Cancer Research launched Women in Cancer Research (WICR), a membership group designed...
Building on advances in technology and analytical tools, real-world data (RWD) sources have attracted increasing interest as means to...
AACR will host the inaugural Blood Cancer Discovery Symposium March 4-6, 2024, featuring experts from all areas of blood...
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.
Each spring, the American Association for Cancer Research (AACR) brings a group of AACR Associate members to Washington, D.C.,...
This post explores the challenges we face with anti-EGFR monoclonal antibody therapies and new strategies researchers have developed to...
It is an exciting era for drug development in oncology. The many discoveries of new molecular targets, coupled with...
Advances against cancer that make it to the clinic are a result of many years of hard work by...
Lung cancer awareness month started hot on the heels of two exciting pieces of news that highlight the promise...
Immuno-oncology has revolutionized treatment for certain types of cancers, but currently it is only effective for about 20 percent...
The American Association for Cancer Research (AACR) and its Minorities in Cancer Research (MICR) membership group today issued a...
Learn about synthetic lethality and approved drugs that use this approach to treat cancer.
Although childhood cancer is rare, it represents the leading cause of death by disease in children in developed countries....
Editor’s note: As President Joseph R. Biden Jr. took office on Wednesday, Cancer Discovery, a journal of the American...
The U.S. Food and Drug Administration (FDA) recently added a new therapeutic to the armamentarium for oncologists treating patients...
A study published recently in the AACR’s journal Cancer Discovery addresses the burgeoning question of the utility of high-throughput...
The flurry of anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) late last month included the...
Back for the new year, here are the editors’ selections for the January issues of the eight scientific journals...
Immune-related adverse events (irAEs) is the collective term used to describe the side effects that arise in response to...
The National Women’s Survivors Convention wrapped up on Saturday, Aug. 2, in Nashville, Tennessee. The convention, just in its second...